Relapsed or Refractory Mantle Cell Lymphoma
1 clinical trials · Condition
◉ Watch Relapsed or Refractory Mantle Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (NCT01833039) | Janssen Biotech, Inc. |
Track Relapsed or Refractory Mantle Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.